Sight Diagnostics builds the OLO, an FDA 510(k)-cleared blood analyzer that uses machine vision and on-device machine learning to deliver a complete blood count in minutes. The company replaces the human microscope observer with automated imaging and runs its models on the device rather than in the cloud. Sight has developed automated sample-preparation breakthroughs and has applied for 20 patents, eight of which have been issued. It has placed devices in hospitals worldwide to collect data and explore additional diagnostic applications, including signals related to COVID-19 severity. The company employs about 100 people, mainly in R&D, and maintains offices in London and New York. With the recent funding it is focusing on expanding in the U.S. market and refining its product beyond the initial complete blood count offering. Sight Diagnostics has developed OLO, a desktop machine that analyzes cartridges loaded with drops of patient blood and uses machine learning and computer vision to produce a complete blood count from a finger‑prick sample. The company positions OLO as a lab‑grade, point‑of‑care alternative to venous draws and central labs, with results available in minutes and a user interface intended for non‑professionals. OLO received CE Mark registration following a 287‑person clinical trial and the company launched the device last summer; it has signed a distribution agreement in Italy and expects customers across multiple European countries this year. Sight is pursuing additional regulatory work in the U.S., having completed U.S. clinical trials and submitted data to the FDA as part of a 510(k) pathway and subsequent CLIA waiver plans. R&D funds will be used to expand the menu of tests for the OLO platform and to tailor procedures and algorithms for use cases such as neonatal screening, oncology, pediatrics, and blood‑disease diagnosis. The company, founded in 2011, has raised more than $50M to date and will use the new capital to accelerate commercial expansion and regulatory efforts. Sight Diagnostics develops OLO, a compact desktop point-of-care blood diagnostics system that uses patented sample digitization and proprietary machine-vision algorithms to produce lab-quality complete blood counts from a finger-prick. The device analyzes single-use cartridges loaded with drops of patient blood and is designed to be simple enough for non-specialist clinic staff to operate. The company obtained a CE Mark after a 287-person clinical study at Shaare Zedek Medical Center and says it compared OLO against a Sysmex XN lab analyzer. Sight has been working on OLO for more than eight years, is conducting a US clinical trial across three sites aiming for 500+ participants using eight instruments, and is pursuing 510(k) FDA clearance followed by a CLIA waiver. Financially, Sight confirms $25 million in equity financing across Series A and B and is in the process of raising a Series C. The team previously commercialized a malaria test (Parasight), selling more than 600,000 tests, and plans to expand OLO as a multi-test platform with each additional assay undergoing independent clinical validation.

Total raised

$124M

Funding rounds

3

Latest round

Series D

Latest activity

Aug 2020